CTRI/2018/02/012248暂停未知
A multicentric, randomized, prospective, open-labelled study to compare the effects of treatment ? versus no treatment ? on neuropsychological and electro-clinical parameters in Indian children with newly diagnosed BECTS
Bharati Vidyapeeth Medical College Pune0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 暂停
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •1. Onset of seizures after the age of 3 years
- •2. History of at least one typical seizure
- •3. Normal neurological and development history
- •4.Clinical and EEG criteria suggestive of BECTS according to ILAE criteria
- •5. No other seizure type
排除标准
- •1. Prior neurological deficits
- •2. Pre-existing psychiatric conditions
- •3. Symptomatic etiology
- •4. 3 or more seizures in last 3 months
- •5. Already on anti-epileptics for more than a week
研究者
相似试验
已完成
3 期
To evaluate safety and efficacy of Trastuzumab, (Manufactured by Intas) in comparison with Reference Biologic (Trastuzumab, Marketed by Roche) in the patients with Metastatic Breast Cancer.CTRI/2015/09/006168Intas Pharmaceuticals Ltd120
招募中
不适用
Compare Sequential and Quadruple Therapy for the Eradication of Helicobacter pylori in KoreaCertain infectious and parasitic diseasesKCT0001176Seoul National University Bundang Hospital390
进行中（未招募）
1 期
Study to evaluate the efficacy and safety of Nicotinamide DS compared to Ciclopirox olamine at 1% cream in seborrheic dermatitis.Patients affected by seborrheic dermatitis.MedDRA version: 21.1Level: PTClassification code 10039793Term: Seborrhoeic dermatitisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2020-000720-19-ITIDI FARMACEUTICI SR102
尚未招募
4 期
To Assess the Safety and Efficacy of Imusil tablet in Treatment of Adult Subjects with mild COVID-19CTRI/2022/02/040687Glowderma Lab Private Limited
已完成
3 期
A Phase 3 study to evaluate the Efficacy, Safety and Tolerability of fixed dose combination of Dapagliflozin 10 mg Gliclazide 60 mg SR tablet in Patients with Type 2 Diabetes Mellitus who are inadequately controlled on Metformin Monotherapy.CTRI/2023/01/049286Eris Life Sciences Limited244